Lori A. Woods has made a noteworthy investment in Perspective Therapeutics, Inc., acquiring 23,750 shares of the company. This transaction took place on November 12, 2026, and was reported in a recent SEC filing. Such insider purchases can signal confidence in the company's future prospects and may attract attention from investors and analysts alike.

Background

Woods is associated with Perspective Therapeutics, Inc., which operates under the SIC code for Pharmaceutical Preparations. The company is based in Seattle, Washington, and has undergone several name changes, with its most recent being from Isoray, Inc. on December 31, 2018. Perspective Therapeutics trades under the ticker symbol CATX.

What the Filing Says

According to the SEC filing, Woods purchased the shares at a weighted average price of $0.8438, with prices ranging from $0.8437 to $0.8438 across multiple transactions. Following this acquisition, Woods now directly owns 28,557 shares of Perspective Therapeutics. The filing states, "The Reporting Person undertakes to provide...full information regarding the number of shares purchased at each separate price in the transactions described."

Impact

This acquisition may have implications for both the company and the broader pharmaceutical industry. Insider purchases often indicate a positive outlook on company performance, potentially influencing other investors' perceptions. Woods' investment could also signal to competitors that Perspective Therapeutics is positioned for growth.

What's Next

The filing does not say what happens next.